Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Bilirubin
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Health benefits == In the absence of liver disease, high levels of total bilirubin confers various health benefits.<ref>{{cite journal |vauthors=Sedlak TW, Snyder SH |date=June 2004 |title=Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle |journal=[[Pediatrics (journal)|Pediatrics]] |volume=113 |issue=6 |pages=1776–82 |doi=10.1542/peds.113.6.1776 |pmid=15173506}}</ref> Studies have also revealed that levels of serum bilirubin (SBR)<ref>{{cite web |url=https://www.slhd.nsw.gov.au/rpa/neonatal/html/newprot/jaund2.html |title=Neonatal Jaundice |publisher=Slhd.nsw.gov.au |date=2009-08-24 |accessdate=2022-03-16 |archive-date=27 January 2023 |archive-url=https://web.archive.org/web/20230127135902/https://www.slhd.nsw.gov.au/rpa/neonatal/html/newprot/jaund2.html |url-status=dead }}</ref> are inversely related to risk of certain heart diseases.<ref name="Novotn">{{cite journal |vauthors=Novotný L, Vítek L |date=May 2003 |title=Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies |journal=[[Experimental Biology and Medicine (Society for Experimental Biology and Medicine journal)|Experimental Biology and Medicine]] |volume=228 |issue=5 |pages=568–71 |doi=10.1177/15353702-0322805-29 |pmid=12709588 |s2cid=43486067}}</ref><ref>{{cite journal |vauthors=Schwertner HA, Vítek L |date=May 2008 |title=Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin |url=https://zenodo.org/record/1258770 |journal=[[Atherosclerosis (journal)|Atherosclerosis]] |volume=198 |issue=1 |pages=1–11 |doi=10.1016/j.atherosclerosis.2008.01.001 |pmid=18343383}}</ref> While the poor solubility and potential toxicity of bilirubin limit its potential medicinal applications, current research is being done on whether bilirubin encapsulated silk fibrin nanoparticles can alleviate symptoms of disorders such as acute pancreatitis.<ref>{{cite journal |last1=Yao |first1=Q. |last2=Jiang |first2=X. |last3=Zhai |first3=Yuan-Yuan |last4=Luo |first4=Lan-Zi |last5=Xu |first5=He-Lin |last6=Xiao |first6=J. |last7=Kou |first7=L. |last8=zhao |first8=Ying-Zheng |date=2020 |title=Protective effects and mechanisms of bilirubin nanomedicine against acute pancreatitis |url=https://www.sciencedirect.com/science/article/abs/pii/S0168365920301863 |journal=[[Journal of Controlled Release]] |volume=332 |pages=312–325 |doi=10.1016/j.jconrel.2020.03.034 |pmid=32243974 |access-date=11 November 2021 |via=[[Elsevier Science Direct]] |s2cid=214786812|url-access=subscription }}</ref> In addition to this, there have been recent discoveries linking bilirubin and its ε-polylysine-bilirubin conjugate (PLL-BR), to more efficient insulin medication. It seems that bilirubin exhibits protective properties during the islet transplantation process when drugs are delivered throughout the bloodstream.<ref name="SciFinderb">{{cite journal |last1=Zhao |first1=Ying-Zheng |last2=Huang |first2=Zhi-Wei |last3=Zhai |first3=Yuan-Yuan |last4=Shi |first4=Yannan |last5=Du |first5=Chu-Chu |last6=Zhai |first6=Jiaoyuan |last7=Xu |first7=He-Lin |last8=Xiao |first8=Jian |last9=Kou |first9=Longfa |last10=Yao |first10=Qing |date=2021 |title=Polylysine-bilirubin conjugates maintain functional islets and promote M2 macrophage polarization |url=https://www.sciencedirect.com/science/article/abs/pii/S1742706120307704#! |journal=[[Acta Biomaterialia]] |volume=122 |pages=172–185 |doi=10.1016/j.actbio.2020.12.047 |pmid=33387663 |access-date=11 November 2021 |via=Elsevier Science Direct |s2cid=230281925|url-access=subscription }}</ref>
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)